Sanofi Drug Shows Long-Term Benefit
Blueprint Medicines, a Sanofi company, announced positive four-year data for its drug AYVAKIT. The study showed sustained benefits and long-term safety for patients with indolent systemic mastocytosis, a rare blood disorder. The results were presented as part of 12 data presentations at the 2026 AAAAI Annual Meeting.
Indolent systemic mastocytosis (ISM) is the most common form of a rare blood disorder where the body produces too many mast cells. These abnormal cells accumulate in the skin, bone marrow, and digestive tract, releasing excessive amounts of histamine that can cause a continuous, allergy-like response affecting multiple organs. The disorder is driven by the KIT D816V mutation in about 95% of cases. AYVAKIT is a tyrosine kinase inhibitor specifically designed to selectively target this mutation, shifting the treatment paradigm from purely managing symptoms to addressing the underlying cause of the disease. Patients with ISM often suffer from a wide range of debilitating symptoms, including skin lesions, flushing, abdominal pain, diarrhea, brain fog, and bone pain. Prior to AYVAKIT's approval, treatment consisted of supportive care medications like antihistamines and steroids, which often failed to provide adequate control. The U.S. Food and Drug Administration (FDA) first approved AYVAKIT for adults with ISM in May 2023, making it the first and only medicine approved to treat the disease. This approval was based on the initial results of the double-blind, placebo-controlled Phase 2 PIONEER trial. Long-term data from the PIONEER study, with a median follow-up of over three years, has shown that AYVAKIT provides sustained symptom control and improves quality of life. The therapy was also found to be well-tolerated, with a low discontinuation rate due to treatment-related adverse events. The PIONEER study measured efficacy through the Indolent Systemic Mastocytosis Symptom Assessment Form (ISM-SAF), a tool developed with patient input. Key secondary goals of the trial included a reduction in objective measures of mast cell burden, such as serum tryptase levels.
